Rivia Secures €13M Series A to Enhance AI Platform for Clinical Trials

Rivia has secured €13 million in Series A funding to enhance its AI platform for managing clinical trials, focusing on the expanding US biotech market. Founded in 2022, the company aims to improve trial efficiency and data integrity amidst a significant increase in data volumes, with plans to scale automation and support international growth. The funding will also help Rivia meet evolving regulatory expectations in drug development.

Published Mar 20, 2026

Rivia has raised €13 million in Series A funding to expand its AI platform for managing clinical trials, targeting the growing US biotech market. Founded in 2022, Rivia integrates fragmented trial data into a cohesive system, improving efficiency and data integrity.

AI-curated by Theia

The clinical trial landscape has seen a 400 percent increase in data volumes, creating demand for innovative solutions. The funding will enhance product development, scale automation capabilities, and support international growth. Rivia aims to improve trial execution and reduce costs, positioning itself to meet evolving regulatory expectations in drug development.